Manifold, an artificial intelligence platform focused on the life sciences industry, has announced an $18 million Series B funding round led by Reach Capital, with additional investment from SilverArc Capital, Industry Ventures, and existing backers TQ Ventures and Calibrate Ventures. This brings the company’s total capital raised to $40 million, solidifying its position as a leading player in vertical AI for biopharmaceuticals and medical research. The funding will support the expansion of Manifold’s AI-driven platform, which is designed to accelerate drug discovery, improve clinical trial design, and enhance decision-making across the life sciences value chain. Manifold’s platform leverages generative AI and advanced data modeling to help biopharma companies analyze vast amounts of scientific literature, molecular data, and clinical information. By integrating structured and unstructured data from diverse sources—including research papers, patents, and trial databases—the platform enables scientists to identify promising drug candidates, predict biological outcomes, and uncover novel therapeutic pathways more efficiently than traditional methods. The company emphasizes that its AI is not just a tool for automation but a collaborative partner in the research process, helping to reduce time and cost in early-stage drug development. The investment comes at a pivotal moment for AI in life sciences, as pharmaceutical companies increasingly turn to machine learning to address long-standing challenges such as high R&D costs, low success rates in clinical trials, and lengthy development timelines. Manifold’s technology is designed to address these issues by providing researchers with real-time, data-driven insights tailored to the complexities of biological systems and disease mechanisms. Reach Capital, a venture firm focused on healthcare and life sciences innovation, led the Series B round, citing Manifold’s unique ability to deliver domain-specific AI solutions that are both scientifically rigorous and operationally effective. “Manifold is building the future of drug discovery by combining deep domain expertise with cutting-edge AI,” said a representative from Reach Capital. “Their platform is not just another generic AI tool—it’s purpose-built for the complexities of life sciences.” The company’s growing momentum reflects broader industry trends. Major pharmaceutical firms and startups alike are investing heavily in AI, with some forming strategic partnerships with AI developers to co-create solutions. Manifold’s approach stands out by focusing exclusively on life sciences, allowing it to develop models trained on high-quality, curated biological data and to align its technology with the regulatory and scientific standards of the industry. Manifold’s leadership team includes experts from both AI and biopharma, ensuring that the platform meets the practical needs of researchers and clinicians. The company has already partnered with several biotech firms and academic institutions to pilot its technology in real-world settings, with early results showing significant improvements in data analysis speed and hypothesis generation. As the life sciences sector continues to embrace digital transformation, Manifold is positioning itself as a key enabler of innovation. The new funding will be used to expand its product suite, enhance its AI models, and grow its team to support increased demand from clients across the biopharma ecosystem. With $40 million in total funding and a clear focus on vertical AI, Manifold is emerging as a category leader in a space where AI is no longer a futuristic concept but a critical component of modern drug development. As the race to bring new therapies to patients accelerates, platforms like Manifold are proving essential in turning vast scientific data into actionable insights—transforming how medicine is discovered and delivered.